Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

Blood - 21 Nov 2024

Döhner Hartmut, DiNardo Courtney D, Appelbaum Frederick R, Craddock Charles, Dombret Hervé, Ebert Benjamin L, Fenaux Pierre, Godley Lucy A, Hasserjian Robert P, Larson Richard A, Levine Ross L, Miyazaki Yasushi, Niederwieser Dietger, Ossenkoppele Gert, Röllig Christoph, Sierra Jorge, Stein Eytan M, Tallman Martin S, Tien Hwei-Fang, Wang Jianxiang, Wierzbowska Agnieszka, Wei Andrew H, Löwenberg Bob

Abstract excerpt

ABSTRACT: The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 39133932
DOI: 10.1182/blood.2024025409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.PMID 39133932Read ↗

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.Semantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Semantic proximity Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML.Semantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

How I treat AML incorporating the updated classifications and guidelines.Semantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG ReportSemantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.